Idexx Laboratories raises FY25 EPS view to $12.81-$13.01 from $12.40-$12.76

Raises FY25 revenue view to $4.270B-$4.300B from $4.205B-$4.280B. Consensus is for FY25 EPS $12.63 and for revenue $4.23B. The company said, ” The Company is increasing its outlook for organic revenue growth to 8.8%-9.5%, an increase of ~1% at midpoint, reflecting the operational performance benefits highlighted above. The Company increased its full year reported operating margin outlook to 31.6% – 31.8%, bringing the projected full year operating profit margin expansion to 260 – 280 basis points as reported and 80 – 100 basis points on a comparable basis. This outlook benefits from strong third quarter operating performance, while advancing strategic investment priorities.”